Polyrizon Ltd. (NASDAQ:PLRZ) Short Interest Down 21.8% in February

Polyrizon Ltd. (NASDAQ:PLRZ) was the recipient of a significant drop in short interest during the month of February. As of February 27th, there was short interest totaling 42,068 shares, a drop of 21.8% from the February 12th total of 53,763 shares. Based on an average trading volume of 32,456 shares, the short-interest ratio is currently 1.3 days. Currently, 4.0% of the shares of the company are sold short. Currently, 4.0% of the shares of the company are sold short. Based on an average trading volume of 32,456 shares, the short-interest ratio is currently 1.3 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Polyrizon in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, Polyrizon has a consensus rating of “Sell”.

Hedge Funds Weigh In On Polyrizon

An institutional investor recently bought a new position in Polyrizon stock. Jane Street Group LLC bought a new position in shares of Polyrizon Ltd. (NASDAQ:PLRZ) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 14,032 shares of the company’s stock, valued at approximately $119,000. Jane Street Group LLC owned 1.35% of Polyrizon as of its most recent SEC filing.

Polyrizon Stock Performance

PLRZ traded down $0.10 during trading on Monday, reaching $14.20. The stock had a trading volume of 25,461 shares, compared to its average volume of 95,171. The stock has a 50 day moving average of $13.85 and a two-hundred day moving average of $9.36. Polyrizon has a 1-year low of $2.88 and a 1-year high of $2,235.00.

Polyrizon Company Profile

Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.